# Rituximab for Schizophrenia Spectrum Disorder (RITS-PS-2019)

> **NCT03983018** · PHASE2 · COMPLETED · sponsor: **Region Örebro County** · enrollment: 9 (actual)

## Conditions studied

- Schizophrenia Spectrum and Other Psychotic Disorders
- Treatment-resistant Schizophrenia

## Interventions

- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT03983018
- **Lead sponsor:** Region Örebro County
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-07
- **Primary completion:** 2022-03-31
- **Final completion:** 2022-03-31
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2025-03-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03983018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03983018, "Rituximab for Schizophrenia Spectrum Disorder (RITS-PS-2019)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03983018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*